z-logo
open-access-imgOpen Access
18F-FDG PET/CT findings in a possible MELAS syndrome: A case study
Author(s) -
Alireza Emami-Ardekani,
Alireza Emami-Ardekani,
Sara Harsini,
Armaghan Fard-Esfahani,
Farzaneh Baseri,
Mohammad Eftekhari
Publication year - 2019
Publication title -
iranian journal of nuclear medicine.
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.128
H-Index - 10
eISSN - 2008-2509
pISSN - 1681-2824
DOI - 10.18502/irjnm.v27i1.976
Subject(s) - medicine , mitochondrial myopathy , lactic acidosis , melas syndrome , encephalopathy , headaches , hemiparesis , asymptomatic , stroke (engine) , leukoencephalopathy , mitochondrial encephalomyopathy , radiology , magnetic resonance imaging , pathology , surgery , mechanical engineering , mutation , biochemistry , chemistry , engineering , mitochondrial dna , gene , angiography
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a rare congenital disorder of mitochondrial DNA, presenting a wide range of clinical symptoms comprising headaches, seizures, aphasia, hearing loss, visual defects, and hemiparesis. Herein we report a case of a previously asymptomatic 40-year-old male who presented with recurrent headache, seizures, Wernicke’s aphasia, and impaired visual acuity. Investigations included CT, MRI, MR venography, MR spectroscopy, and PET/CT with 18F-fluorodeoxyglucose (18F-FDG-PET) of the brain. PET imaging showed diffuse increased 18F-FDG uptake in the right hemisphere and left temporal lobe; additionally, decreased 18F-FDG uptake was observed in the left frontoparietal lobe. The patient underwent treatment by levetiracetam, co-enzyme Q10, riboflavin, L-carnitine, and lacosamide, followed by improvement of his clinical signs and symptoms indicative of partial response to the therapy. Key

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here